"Das St. Bernward Krankenhaus in Hildesheim ist ein mit 508 Betten und moderner Medizintechnik ausgestattetes Schwerpunktkrankenhaus mit christlicher Tradition. Unsere rund 1.600 Mitarbeiter versorgen mehr als 27.000 Patienten stationär und 60.000 ambulant. Zu unserem Leistungsspektrum zählen neben 17 Kliniken auch vier Institute, mehrere zertifizierte Zentren und Fachärztezentren, fünf Medizinische Versorgungszentren und unser Ambulantes Operationszentrum. Seit 2013 gehört das St. Bernward Krankenhaus zum Elisabeth Vinzenz Verbund. Wir sind akademisches Lehrkrankenhaus der Georg-August-Universität in Göttingen und bilden jährlich 180 Alten-, Gesundheits- und Krankenpflege-, Kinderkrankenpflegefachkräfte und Hebammen aus."

During the past decade, St. Bernward-Krankenhaus conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Bernward-Krankenhaus" #1 sponsor was "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 3 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "University of Jena" with 2 trials sponsored, "Andramed GmbH" with 1 trials sponsored and "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Bernward-Krankenhaus" #1 collaborator was "Celgene" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Masaryk University" with 1 trials as a collaborator, "Roche Pharma AG" with 1 trials as a collaborator and "Study Alliance Leukemia (SAL) Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "St. Bernward-Krankenhaus" are "Lymphoma" (3 trials), "B-cell Lymphoma" (1 trials), "Chronic Myeloid Leukemia" (1 trials), "Colorectal Adenoma With Mild Dysplasia" (1 trials) and "Colorectal Adenoma With Severe Dysplasia" (1 trials). Many other conditions were trialed in "St. Bernward-Krankenhaus" in a lesser frequency.

Most popular intervention types in "St. Bernward-Krankenhaus" are "Drug" (10 trials), "Biological" (3 trials), "Procedure" (3 trials), "Other" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (3 trials), "doxorubicin hydrochloride" (3 trials), "prednisone" (3 trials), "rituximab" (3 trials) and "vincristine sulfate" (3 trials). Other intervention names were less common.

The vast majority of trials in "St. Bernward-Krankenhaus" are 13 trials for "All" genders.

Currently, there are NaN active trials in "St. Bernward-Krankenhaus". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in St. Bernward-Krankenhaus, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in St. Bernward-Krankenhaus, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".